Search Results
May 06, 2026, 09:00 ET Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor
More news about: Eli Lilly and Company
May 03, 2026, 08:16 ET TTW Reveals 50 Best Eco Tourism Destinations in the World for 2026
transport to eco tourism zones across the island.11. Costa Rica – Corcovado National ParkCorcovado National Park, located on the Osa Peninsula, is one of the most biologically rich eco tourism destinations, known for dense rainforests, coastal habitats, and extraordinary biodiversity.
More news about: Travel And Tour World
Apr 30, 2026, 19:02 ET /C O R R E C T I O N -- Amgen/
mildly reduced ejection fraction and obesity.MARITIME-OSA-1, a Phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea on positive airway pressure therapy and living with obesity or overweight.MARITIME-OSA-2, a Phase 3 study of MariTide, is enrolling adults living
More news about: Amgen
Apr 29, 2026, 08:00 ET MellingMedical Links Up with TAP Sleep Care to Deliver Oral Appliance Therapy Throughout the Federal Healthcare System
Management of OSA, which suggests Oral Appliance Therapy (OAT) as first-line therapy for mild to moderate OSA.The guidelines highlight that OAT can achieve equivalent health outcomes to Positive Airway Pressure (PAP) therapy in certain populations—such as Veterans with PTSD and OSA—while delivering
More news about: MellingMedical
Apr 09, 2026, 09:00 ET Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
III stage of its global development for three proposed indications: obesity/overweight, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA). Existing clinical data demonstrate that Bofanglutide can effectively reduce body weight and blood glucose levels while comprehensively improving other
More news about: Gan & Lee Pharmaceuticals
Apr 06, 2026, 08:00 ET Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA and Apnimed plans
More news about: Apnimed, Inc.
Mar 31, 2026, 08:00 ET Snoring and Sleep Apnea Accelerate Vascular Aging
independent of traditional risk factors such as blood pressure or BMI. Previous research investigating the relationship between obstructive sleep apnea (OSA) and PWV has yielded inconsistent results. One reason is that most studies relied on single-night measurements that fail to capture the natural night-to-night
More news about: Withings
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1
More news about: Eli Lilly and Company
Mar 27, 2026, 10:15 ET MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
application for a next-generation OSA device engineered for MRI compatibility, remote configuration management, and rechargeable battery technology projected to last up to 15 years, with a targeted launch in the first half of 2027. The aura6000 approval addresses a broad OSA patient population, having been
More news about: Equity Insider
Mar 24, 2026, 10:15 ET Digital Dentistry Market to Reach US$ 13.7 Billion by 2033 Expands Amid Rapid Technological Adoption and Precision Care Demand - Persistence Market Research
Respiratory Diagnostics Market by Test Type (Mechanical, OSA, Imaging, Molecular Test), by Disease (Tuberculosis, COPD, Lung Cancer), by Diagnosis Type (Syndromic, Aetiological, Prognosis), and Regional Analysis
More news about: Persistence Market Research Pvt. Ltd.
Mar 24, 2026, 09:00 ET Crooked Pop™ Launches a New Era of Clean Alcohol with USDA-Certified Organic, Zero-Sugar Hard Soda
approach to ready-to-drink (RTD) alcohol, powered by Organic Super Dry Alcohol (OSA); a proprietary fermentation innovation developed over four years. Derived from ancient grains including quinoa, amaranth, millet, and cassava, OSA creates a clean, neutral alcohol base without the need for distilled spirits,
More news about: Crooked
Mar 24, 2026, 08:00 ET Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109
individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA and Apnimed plans
More news about: Apnimed, Inc.
Mar 19, 2026, 06:23 ET Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China
5.0 for Chinese hemophilia B patients receiving prophylactic treatment. The mean FIX:C level at week 52 after gene therapy was 55.1 IU/dL (SD35.9) (OSA, SynthAsil). The average number of infusions of coagulation FIX drug decreased from 58.2 times/year (SD 30.67) before gene therapy treatment to 2.9 times/year
More news about: Belief BioMed
Mar 18, 2026, 13:54 ET Brandwatchin raportin mukaan vain 25 % markkinoijista todella ymmärtää kohdeyleisöään
sosiaalisen median hallinnoinnin, joiden avulla brändit ja virastot voivat toteuttaa datapohjaisia strategioita laajassa mittakaavassa.Brandwatch on osa Cisionin brändiperhettä yhdessä CisionOnen, Trajaanin ja PR Newswiren kanssa.Median yhteystiedot:Cision Public Relations
More news about: Brandwatch Ltd.
Mar 11, 2026, 15:00 ET ONTARIO SUPERIOR COURT OF JUSTICE CERTIFIES SECURITIES MISREPRESENTATION CLASS ACTION AGAINST BARRICK GOLD CORPORATION
Plaintiffs' primary market claims under s. 130.1 of the OSA.Justice Leiper also awarded Plaintiffs' Counsel costs of the leave motions totaling $2.75 million, inclusive of fees, disbursements, and taxes. This is the largest costs award, on an OSA leave motion, to date.The Defendants deny
More news about: Rochon Genova
Mar 06, 2026, 01:36 ET Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
implications across multiple organ systems. Obesity related diseases encompass a broad spectrum of conditions including cardiovascular disease, T2DM, MASH, OSA and numerous other comorbidities. Lifestyle intervention remains the cornerstone of overweight and obesity management. When lifestyle modifications alone
More news about: Sciwind Biosciences Co., Ltd.
Mar 05, 2026, 23:53 ET 全球首個偏向型GLP-1減重藥物先維盈®獲批上市
致病因素，肥胖症已成為我國重大公共衛生問題，是我國第六大致死/致殘主要危險因素。超重/肥胖症是一個多方面的健康挑戰，對多個器官系統產生深遠影響。肥胖相關疾病涵蓋範圍廣泛，包括心血管疾病、2 型糖尿病、MASH、OSA、血脂異常、高血壓、骨關節炎、慢性腎病、肌肉骨骼疾病、某些癌症以及眾多其他併發症。目前生活方式干預是超重/肥胖症的基礎且重要手段，但當生活方式干預無法達到減重目標時，可聯合應用減重藥物進行治療。關於埃諾格魯肽埃諾格魯肽注射液（Ecnoglutide injection，曾用名：伊諾格魯肽）是由先為達生物自主研發的全球首個獲批的cAMP偏向型
More news about: 杭州先為達生物科技股份有限公司
Mar 05, 2026, 06:00 ET Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor
More news about: Eli Lilly and Company
Feb 27, 2026, 07:09 ET PHYSICALMIND Institute julkaisee "WELLVILLE" PSA:n uuden tutkimuksen osoittaessa, että painoindeksi saattaa olla vanhentunut
määritelmä on saanut tukea 76 organisaatiolta, joihin lukeutuu myös American Heart Association."Jos vyötärönympärys otetaan huomioon, suurin osa amerikkalaisista aikuisista ylittää liikalihavuuden 35 tuuman raja-arvon", sanoi PHYSICALMIND-instituutin perustaja Joan Breibart, joka on tunnettu Pilates-menetelmän
More news about: PhysicalMind Institute
Feb 26, 2026, 06:30 ET Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
obesity or overweight with at least one weight-related medical problem. It is also being studied as a potential treatment for obstructive sleep apnea (OSA) and hypertension in adults with obesity.About ACHIEVE-3 and ACHIEVE clinical trial programACHIEVE-3 (NCT06045221) is a Phase
More news about: Eli Lilly and Company
Feb 23, 2026, 09:00 ET Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
to lose excess body weight and keep the weight off. Zepbound may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor
More news about: Eli Lilly and Company
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
weight-related medical problems to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and
More news about: Eli Lilly and Company
Feb 10, 2026, 10:00 ET NATO on valinnut Brandwatchin ja Blackbird.AI-konsortion tietoympäristön arviointivalmiuksien toimittajaksi
median hallinnoinnin, joiden avulla brändit ja virastot voivat toteuttaa datapohjaisia strategioita laajassa mittakaavassa.Brandwatch on osa Cisionin brändiperhettä yhdessä CisionOnen, Trajaanin ja PR Newswiren kanssa.Tietoa Blackbird.AI:stäBLACKBIRD.AI
More news about: Cision Ltd.
Feb 03, 2026, 16:01 ET AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
mildly reduced ejection fraction and obesity.MARITIME-OSA-1, a Phase 3 study of MariTide, is enrolling adults living with obstructive sleep apnea on positive airway pressure therapy and living with obesity or overweight.MARITIME-OSA-2, a Phase 3 study of MariTide, is enrolling adults living
More news about: Amgen
Jan 16, 2026, 10:27 ET Envision lanza Dubhe, dando forma al sistema de energía de IA con el primer modelo de base energética del mundo
diseñado para dar forma al sistema físico de IA más grande del mundo: el sistema de energía de IA. Inspirado en Dubhe, la estrella guía de la Osa Mayor que ha ayudado a la humanidad a navegar por la Estrella del Norte durante miles de años, el modelo de la base energética de Dubhe fue presentado
More news about: Envision Energy